Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Methylphenidate
Drug ID BADD_D01431
Description Methylphenidate is a central nervous system stimulant used most commonly in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and for narcolepsy. Also known as the marketed products Ritalin, Concerta, or Biphentin, methylphenidate is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve the following group of developmentally inappropriate symptoms associated with ADHD: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. Long-acting formulations of psychostimulants such as methylphenidate, [DB01576], and [DB01255] are considered the most effective and widely used treatment for ADHD, and are considered first-line options for children, adolescents, and adults as recommended by CADDRA (Canadian ADHD Resource Alliance). [L6037] CADDRA recommends the use of methylphenidate due to long term studies, of over twenty years in duration, which show methylphenidate is safe and effective.
Indications and Usage Methylphenidate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older and for the treatment of narcolepsy.
Marketing Status approved; investigational
ATC Code N06BA04
DrugBank ID DB00422
KEGG ID D04999
MeSH ID D008774
PubChem ID 4158
TTD Drug ID D02PPN
NDC Product Code 0781-2363; 0378-8263; 0574-2420; 0406-7654; 70165-200; 0378-8261; 68968-5552; 68968-5555; 70165-100; 0781-2362; 0781-2364; 0378-8262; 0574-2410; 0574-2430; 0574-2415; 68968-5553; 70165-300; 68968-5554; 0781-2361; 0378-8260
UNII 207ZZ9QZ49
Synonyms Methylphenidate | Metadate | Equasym | Methylin | Concerta | Phenidylate | Ritalin | Ritaline | Ritalin-SR | Ritalin SR | Tsentedrin | Centedrin | Daytrana | Methylphenidate Hydrochloride | Hydrochloride, Methylphenidate
Chemical Information
Molecular Formula C14H19NO2
CAS Registry Number 113-45-1
SMILES COC(=O)C(C1CCCCN1)C2=CC=CC=C2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Eye oedema06.08.03.0130.000090%Not Available
Lymphatic disorder01.09.01.003--Not Available
Drug tolerance08.06.01.0030.000160%Not Available
Musculoskeletal discomfort15.03.04.0010.000111%Not Available
Application site swelling12.07.01.027; 08.02.01.0270.000140%Not Available
Thermal burn23.03.11.042; 12.05.04.001--
Growth retardation14.03.02.031; 05.03.02.007; 15.03.05.0160.000699%
Depressive symptom19.15.02.0030.000041%Not Available
Affect lability19.04.01.0010.000703%Not Available
Transaminases increased13.03.04.036--Not Available
Cerebral disorder17.02.10.0170.000111%Not Available
Dysphemia19.19.03.005; 17.02.08.0100.000201%Not Available
Haemorrhage24.07.01.002--Not Available
Painful erection21.03.01.0090.000160%Not Available
Faecaloma07.01.03.0040.000041%Not Available
Daydreaming19.21.02.0050.000090%Not Available
Hypoaesthesia oral17.02.06.021; 07.05.05.0030.000090%Not Available
Bipolar disorder19.16.01.0030.000267%Not Available
Cognitive disorder19.21.02.001; 17.03.03.003--
Major depression19.15.01.0030.000082%Not Available
Precocious puberty21.03.02.009; 05.05.03.0010.000206%
Metabolic disorder14.11.01.0010.000090%Not Available
Dysgraphia17.02.03.0060.000041%Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Application site discolouration12.07.01.030; 23.03.03.023; 08.02.01.0300.000641%Not Available
Angiopathy24.03.02.007--Not Available
Extremity necrosis24.04.03.0120.000041%Not Available
Blood alkaline phosphatase increased13.04.02.004--
Induration08.01.03.020--Not Available
Hepatic enzyme increased13.03.04.028--Not Available
The 18th Page    First    Pre   18 19 20 21 22    Next   Last    Total 23 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene